Related Experiment Video
Updated: Jan 15, 2026
07:15
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
10.3K
Targeting gut-liver-kidney axis: microbiota-derived metabolites and therapeutic implications
Yufei Zhang1,2, Cuiting Sun3, Yudian Wang1,2
1College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Cell Communication and Signaling : CCS
|January 13, 2026
Summary
The gut-liver-kidney axis links gut health to liver and kidney function via microbial metabolites. Targeting this axis with diet, probiotics, or drugs may restore metabolic homeostasis.
Area of Science:
- Gastroenterology and Hepatology
- Nephrology
- Microbiology
- Metabolic Medicine
Background:
- The gut-liver-kidney axis is crucial for metabolic and immune homeostasis.
- Gut microbiota and host metabolism dynamically interact, influencing systemic health.
- Dysbiosis and leaky gut allow microbial metabolites to impact liver and kidney function.
Purpose of the Study:
- To review molecular mechanisms of gut-derived metabolites in liver and kidney pathology.
- To examine the
Main Methods:
- Literature review focusing on molecular mechanisms and inter-organ signaling.
- Analysis of the
- Main_Results_and_Conclusions_and_Meta_Description_and_TL_DR_and_Enhanced_Abstract_and_Area_of_Science_and_Background_and_Purpose_of_the_Study_and_Main_Methods_and_Main_Results_and_Conclusions
Main Results:
- Gut metabolites like SCFAs, BAs, TMAO, and tryptophan derivatives influence hepatic lipid metabolism and renal immunity.
- Impaired gut barrier function contributes to a
- Conclusions_and_Meta_Description_and_TL_DR_and_Enhanced_Abstract_and_Area_of_Science_and_Background_and_Purpose_of_the_Study_and_Main_Methods_and_Main_Results
Conclusions:
- Understanding gut-organ crosstalk is key for treating metabolic diseases.
- Therapeutic strategies include probiotics, FMT, dietary changes, and pharmacological detoxification.
- A
- Meta_Description
Keywords:
Gut–liver–kidney axisMicrobial metabolitesShort-chain fatty acidsTherapeutic strategiesTrimethylamine-N-OxideMore Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
210
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
210
01:16Drug Biotransformation: Overview
3.6K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.6K
01:28Drug Biotransformation: Overview
2.4K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.4K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:19Factors Affecting Drug Biotransformation: Biological
516
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
516